Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
종목 코드 TTNP
회사 이름Titan Pharmaceuticals Inc
상장일Jan 18, 1996
CEOMr. Weei Jye Chay
직원 수- -
유형Ordinary Share
회계 연도 종료Jan 18
주소Suite 505
도시SAN FRANCISCO
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호94080
전화14152444990
웹사이트https://www.titanpharm.com/
종목 코드 TTNP
상장일Jan 18, 1996
CEOMr. Weei Jye Chay
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음